ArticleCell discovery2024

Targeting SNRNP200-induced splicing dysregulation offers an immunotherapy opportunity for glycolytic triple-negative breast cancer.

Wenxiao Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.